
Emerging SME Services · NSE
Zenith Drugs Limited, founded in 2000, is a pharmaceutical company that manufactures and trades affordable, high-quality medicines, including various generic products. The company operates under WHO-GMP guidelines and holds an ISO 9001:2015 certification, reflecting its focus on quality. It offers a wide product range such as ORS powder, liquid orals, ointments, liquid externals, and capsules, with over 600 products approved by the Food & Drugs Administration and 325 currently in production. Zenith Drugs is expanding by setting up a new manufacturing facility in Muradpura, Depalpur, Indore, and it also exports its products to multiple regions including Central America, Africa, Southeast Asia, and South Asia. The company provides third-party manufacturing services to well-known pharmaceutical brands like Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, and as of March 31, 2023, it employs 89 people, including both payroll and contract staff.
Price Band
₹75 – ₹79
Issue Size
₹40.68 Cr
Lot Size
1600 shares
GMP
+44.3%
Est. Listing
₹114
at current GMP
Subscribed
179.07x
overall
Open
19 Feb 2024
Close
22 Feb 2024
Allotment
23 Feb 2024
Refund
24 Feb 2024
Demat Credit
25 Feb 2024
Listing
27 Feb 2024
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹79
Band: ₹75 – ₹79
Estimated Listing Price
₹114
Upper price + GMP
Lot Size
1600 shares
Min investment ₹1,26,400
Estimated Profit / Lot
₹56,000
1600 × ₹35
Grey Market Premium trend
+₹35
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | +₹35 | 44.3% | ₹114 |
| 30 Oct 2026 | +₹35 | 44.3% | ₹114 |
| 29 Oct 2026 | +₹32 | 39.9% | ₹111 |
GMP is unofficial market data. Not a guarantee of listing performance.
Zenith Drugs Limited is bringing an initial public offering (IPO) in the Emerging SME Services sector with an aggregate issue size of ₹40.68 Crores. The shares are offered at a price band of ₹75 to ₹79 per equity share on NSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 1600 shares (approx. ₹1,26,400 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2024-02-25, while un-allotted funds or UPI block mandates will be released on 2024-02-24.
The latest grey market premium for Zenith Drugs Limited IPO is ₹35, which indicates an expected listing price of ₹114.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.